Prostate-specific antigen velocity (PSAV) and PSAV per initial volume (PSAVD) for early detection of prostate cancer in chinese men

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5529-5533

  Zheng, Xiang Yi ^a   Zhang, Peng ^a   Xie, Li Ping ^a   You, Qi Han ^a   Cai, Bo Sen ^b   Qin, Jie ^a  

^a Department of Urology ^*  (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Prostate biopsy; Prostate cancer; PSA velocity; PSAV per initial volume

Indexed keywords

EID: 84874082952     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5529     Document Type: Article

References (24)

1. Allan RW, Sanderson H, Epstein JI (2003). Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol, 170, 370-2.
2. Bretton PR, Evans WP, Borden JD, Castellanos RD (1994). The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma. Cancer, 74, 2991-5.
3. Carter HB, Ferrucci L, Kettermann A, et al (2006). Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst, 98, 1521-7.
4. Carter HB, Pearson JD, Metter EJ, et al (1992). Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA, 267, 2215-20.
5. Catalona WJ, Southwick PC, Slawin KM, et al (2000). Comparison of percent free psa, psa density, and age-specific psa cutoffs for prostate cancer detection and staging. Urology, 56, 255-60.
6. Choi SY, Chang IH, Kim YS, et al (2011). Prostate specific antigen velocity per prostate volume: a novel tool for prostate biopsy prediction. Urology, 78, 874-9.
7. Chang YL, Lin AT, Chen KK, et al (2006). Correlation between serum prostate specific antigen and prostate volume in Taiwanese men with biopsy proven benign prostatic hyperplasia. J Urol, 176, 196-9.
8. De Visschere P, Oosterlinck W, De Meerleer G, Villeirs G (2010). Clinical and imaging tools in the early diagnosis of prostate cancer, a review. JBR-BTR, 93, 62-70.
9. Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM (2007). Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst, 99, 1510-5.
10. Kawachi MH, Bahnson RR, Barry M, et al (2010). Prostate cancer early detection. J Natl Cancer Inst, 8, 240-62.
11. Li M, Zhang S, Ma J, Chen W, Na Y (2009). A comparative study on incidence trends of prostate cancer in part of cities and counties in China. Chin J Urol, 30, 568-70.
12. McLaren DB, McKenzie M, Duncan G, Pickles T (1998). Watchful waiting or watchful progression? Cancer, 82, 342-8.
13. Rhodes T, Girman CJ, Jacobsen SJ, et al (1999). Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol, 161, 1174-9.
14. Schmid HP, Riesen W, Prikler L (2004). Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol, 50, 71-8.
15. Schroder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH (2006). Does psa velocity predict prostate cancer in pre-screened populations? Eur Urol, 49, 460-5;
16. discussion 5. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
17. Smith DS, Catalona WJ (1994). Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol, 152, 1163-7.
18. Terris MK, Stamey TA (1991). Determination of prostate volume by transrectal ultrasound. J Urol, 145, 984-7.
19. Thompson IM, Ankerst DP, Chi C, et al (2006). Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst, 98, 529-34.
20. Ulmert D, Serio AM, O'Brien MF, et al (2008). Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol, 26, 835-41.
21. Vickers AJ, Wolters T, Savage CJ, et al (2009). Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol, 56, 753-60.
22. Wolters T, Roobol MJ, Bangma CH, SchrÖder FH (2009). Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? european randomized study of screening for prostate cancer (rotterdam). Eur Urol, 55, 385-93.
23. Xie LP, Bai Y, Zhang XZ, et al (2007). Obesity and benign prostatic enlargement: a large observational study in China. Urology, 69, 680-4.
24. Zheng XY, Xie LP, Wang YY, et al (2008). The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. J Cancer Res Clin Oncol, 134, 1207-10.